Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

Ewa Snaar-Jagalska, Shuning He and colleagues from IBL, LION and LACDR reported on a new zebrafish study to understand micrometastasis of human cancer cells. They discovered a novel role for neutrophils in assisting metastasis formation, which provides critical insights for anti-cancer therapies.

As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.

Ariane Briegel wants to use bacteria to detect cancer at an early stage. Together with postdoc Alise Muok, she is developing a method to quickly and cheaply test the urine of patients for the presence of suspicious molecules. They receive a grant of approximately 150,000 euros from the Dutch Cancer…

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

An overview of the research at the Cancer Dug Target Discovery group.

With a Vici grant of 1.5 million euros, Professor of Mathematical biology Roeland Merks will look for ways to fix messy and leaky blood vessels in tumours. His research combines mathematical simulations and lab experiments in a unique way.

Helping cancer patients with treatment choices.

PhD defence

An overview of the research at the Biologics Formulation group

During illness, the stiffness or viscosity of cells can change. Tom Evers demonstrated this by measuring such properties of human immune cells for the first time. ‘The stiffness of certain cells could be a way to make a diagnosis,’ Evers said. He defended his thesis on March 26th.

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by ISA Pharmaceuticals B.V. (a Leiden-based biotechnology company) and the Leiden University Medical Center (LUMC) shows that this vaccine produces a more robust response…

Chemist Gerjan de Bruin has designed a method of slowing down the degradation process of proteins in cells. This may contribute to new cancer medicines with fewer side-effects. PhD defence on 1 June.

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

With cancer, the immune system is a double-edged sword: it can attack tumour cells, but can also help them grow and spread. It is a question of harnessing it. This is what Professor Karin de Visser argued in her inaugural lecture on 15 November 2019.

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

Supervisor: Indira Nederpelt

Leiden chemists, together with colleagues at the University of York (UK) and Technion (Israel) have discovered a small, sugar-like molecule that maintains the integrity of tissue around a tumour during cancer. This molecule prevents tumour cells from spreading from the primary cancer site to colonise…

On 11 November Professor of Gastroenterology and Hepatology, Monique van Leerdam will deliver her inaugural lecture entitled, ‘Aiming for Prevention’. Van Leerdam, who specialises in hereditary tumours, was appointed professor in July 2020. In her inaugural lecture she will discuss the importance of…

Medical Delta has appointed seven professors who will bridge the medical worlds of Leiden, Delft and Rotterdam.

The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.

Liposomes hold great promise for peptide-based personalized cancer vaccination, especially when administered intradermally. However, current liposome preparation methods are very time consuming (resulting in long development times per formulation), whereas personalized cancer vaccination requires very…

In 2013, Sylvestre Bonnet received an ERC Starting Grant to kill cancer with molecules that can be activated by light. Two postdocs and three PhD students later, the end approaches of his so far successful project.

The current projects of the Molecular Physiology group focus on proteins of the endocannabinoid system, kinases and antibacterial targets. MSc- and BSc-students can contact Jessica van Krimpen-Kraaijenoord to apply for research internships.

Death in all types of melanomas is generally caused by metastasis. Uveal melanoma (UM) is the most common intraocular melanoma, there are currently no (patient-derived) animal models that faithfully recapitulate metastatic dissemination of UM.

Researchers from the Leiden University Medical Center (LUMC) have developed an AI model that accurately predicts the risk of endometrial cancer recurrence.

When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.

Seven talented female scientists join the fight against cancer of the Oncode Insitute. Laura Heitman of the Leiden Academic Centre for Drug Research is one of the new Junior Investigators. ‘I hope to discover new druggable targets’.

Thanks in part to the persistence of a Leiden research group, cancer could be detected in the near future with just a single drop of blood. Not only can the diagnosis be determined at an earlier stage, but the blood test is also cheap, fast and patient friendly. The first results of this method seem…

Leiden researchers have carried out successful tests using a new method of packaging a cancer vaccine in nano-particles. The new vaccine has induced a strong immune reaction in mice. The researchers believe that this method can make an important contribution to the treatment of cancer. Their findings…

An overview of awards and prizes granted to our staff and students in 2017, as well as special appointments and royal distinctions.

Predicting cancer survival with machine learning, that is the aim of a new collaboration between the Mathematical Institute, the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels and Leiden University Medical Center. The focus of this project is to characterise the model…

Within the ICM 2018 project, Leiden University cooperated with 25 partner universities from 14 countries. In total, 97 mobilities were granted to this project - 65 mobilities were realised (some mobilities had to be ended prematurely due to covid-19, others were finished online).

Aukje Beers combined theory and practice, as well as chemistry, biology, and computer models. In this way, she discovered two protein inhibitors during her master’s project that could contribute to the development of a new cancer drug. For her research, Beers received the Unilever Research Prize on…

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

Professor of Cardiothoracic Surgery, in particular pulmonary surgery, Jerry Braun will give his inaugural lecture on Friday 23 September entitled ‘Out of countless millions’. Braun has been a professor and acting head of the LUMC’s Department of Cardiothoracic Surgery since January 2020. Covid meant…

The goal of the research presented in this thesis was to explore the chemical space of ruthenium(II) photocages, investigate their ability to host potent chemotherapy drugs, and to red shift the activation wavelength of the most promising PACT candidates to conduct biological studies.

To develop good cancer treatments, we need to know much more about how malignant tumour cells develop. Professor Ewa Snaar-Jagalska looks at not just the effect of medication on isolated cells but also the behaviour of cancer cells in their tissue environment. Inaugural lecture on 11 December.

An international group of scientists has discovered that certain cells of our immune system – the so-called T cells – communicate with each other and work together as a team. To fight an infection they stimulate each other’s growth, but at the same time, they inhibit each other when there is a surplus…

Chemotherapy that does not harm the body, but effectively fights cancer cells: that is the goal of chemist Sylvestre Bonnet and his team. During his PhD research, chemist Xuequan Zhou brought that goal a little closer. He developed molecules that, upon injection in the bloodstream, self-assemble into…

In order to be able to develop effective medicine and treatments to prevent or cure autoimmune diseases or cancer we need to understand the mechanisms how they arise and what drives their course.Unravelling the fundamental molecular mechanisms influencing the onset and course of diseases such as allergies,…

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…

PhD candidate Dennis Wander searches for the best of both worlds. That is to say: a cancer drug that is effective and also has minimal side effects. To this end, he makes new molecules inspired by two existing medicines. And not without result: ‘We have created a new variant that is very promising.’…

PhD defence